IRONWOOD PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Noncontrolling Interest
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$29.32 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2025-03-31
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-12-31 was -$658.00K.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-09-30 was -$1.37M.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$27.29M.
- IRONWOOD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$29.32M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$658.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$2.03M derived: sum of 2 quarters · filed 2025-03-31 | -$29.32M derived: sum of 3 quarters · filed 2025-03-31 | -$29.32M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$1.37M 10-Q · filed 2024-11-07 | -$28.66M derived: sum of 2 quarters · filed 2024-11-07 | -$28.66M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$27.29M 10-Q · filed 2024-08-08 | -$27.29M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |